Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Studieoversikt
Status
Status
Forhold
Forhold
Detaljert beskrivelse
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85710
- Desert Sun Clinical Research
-
-
California
-
Pomona, California, Forente stater, 91767
- REMEK Research
-
San Diego, California, Forente stater, 92101
- Sharp Rees-Stealy
-
Santa Monica, California, Forente stater, 90404
- Southern California Medical Gastroenterology Group, Inc
-
-
Florida
-
Miami, Florida, Forente stater, 33173
- Miami Research Associates
-
-
Georgia
-
Marietta, Georgia, Forente stater, 30067
- Atlanta Gastroenterology Associates
-
-
Illinois
-
Rockford, Illinois, Forente stater, 61107
- Rockford Gastroenterology Associates, Ltd.
-
-
Louisiana
-
Metairie, Louisiana, Forente stater, 70006
- New Orleans Research Institue
-
-
Maryland
-
Columbia, Maryland, Forente stater, 21045
- Columbia Medical Practice
-
-
Pennsylvania
-
Perkasie, Pennsylvania, Forente stater, 18944
- Main Line Gastroenterology
-
-
Texas
-
Austin, Texas, Forente stater, 78705
- Professional Quality Research, Inc.
-
-
Utah
-
Ogden, Utah, Forente stater, 84405
- Advanced Research Institute
-
Sandy, Utah, Forente stater, 84094
- Advanced Research Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Subject is male or female, 50-84 years of age, inclusive.
- Subject is at average risk for development of CRC and has undergone a screening colonoscopy with a normal result at least 30 days and no more than 120 days before providing a stool sample for the study. For the purposes of this study, a "normal" colonoscopy result is defined as no polyps of any size detected or removed (including benign, hyperplastic polyps).
- Subject is able to understand the study procedures, and is able to provide signed consent to participate in the study and authorizes release of relevant protected health information through signing a HIPAA consent.
- Subject is able and willing to provide stool samples at least 30 days and no more than 120 days after undergoing a colonoscopy that resulted in normal findings, according to the written instructions provided to them.
Exclusion Criteria:
- Subject has any condition which, in the opinion of the investigator should preclude participation in the study.
- Subject had any findings on recent or any previous colonoscopy including benign, and/or hyperplastic polyps of any size. (Note: Tissue biopsies that result in no histopathology findings are acceptable.)
- Subject has a history or recent diagnosis of CRC or adenoma.
- Subject has a history of aerodigestive tract cancer.
- Subject has had a positive fecal occult blood test or FIT within the previous six (6) months.
- Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease.
- Subject has had overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)
Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:
- Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
- Greater than or equal to (>=)2 first-degree relatives who have been diagnosed with colon cancer. (Note: first-degree relatives include parents, siblings and offspring).
- One first-degree relative with CRC diagnosed before the age of 60.
- Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP).
- Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome").
- Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Bare etui
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
|---|
|
Average risk patients
Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sensitivity and Specificity of the Exact CRC diagnostic screening test.
Tidsramme: 10 months
|
The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.
|
10 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studiestol: Graham Lidgard, PhD, Chief Scientific officer
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- Exact Sciences 2011-N
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .